Login to Your Account


Heading off investor pain

Though analysts seemed uncertain in February about the commercial future despite favorable phase III data, they came away upbeat from a meeting last week with Trevena Inc. about injectable Olinvo (oliceridine) for moderate to severe acute pain. more »


Analysis

Merck & Co. Inc. took cardiovascular disease (CVD) experts – and, perhaps, some of its own decision-makers – by surprise last month when it disclosed that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of its cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, met its primary endpoint by reducing major coronary events (defined as the composite of coronary death, myocardial infarction and coronary revascularization) compared to placebo in patients at risk for cardiac events who were already receiving a regimen to lower low-density lipoprotein, or LDL.

read more »

Our Habitat for All Things Science
Genome therapy promises new blood disease treatments

HONG KONG – In a study led by Australian scientists at University of New South Wales (UNSW), introducing a beneficial natural mutation into blood cells using gene-editing was shown to stimulate production of fetal hemoglobin (Hb), a finding that could lead to a cure for blood diseases.

People with potentially life-threatening blood disorders, such as thalassemia or sickle cell anemia (SCA), have impaired adult Hb, so require life-long treatment with blood transfusions and medications.

READ MORE »

Opinion


Partners in Focus